DACRA 089
Alternative Names: DACRA-089; KBP-089Latest Information Update: 02 Oct 2021
At a glance
- Originator KeyBioScience
- Developer Eli Lilly and Company; KeyBioScience
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Amylin receptor agonists; Calcitonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 04 Apr 2019 Phase-I clinical trials in Type 2 diabetes mellitus (Treatment-experienced) in Germany (SC) (NCT03907202)
- 31 Jul 2018 No development reported - Preclinical for Non-alcoholic fatty liver disease in Denmark (SC)
- 31 Jul 2018 No development reported - Preclinical for Non-alcoholic steatohepatitis in Denmark (SC)